SAGE Therapeutics (NASDAQ:SAGE) issued its earnings results on Tuesday. The biopharmaceutical company reported ($2.63) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($2.41) by ($0.22), MarketWatch Earnings reports. During the same quarter in the previous year, the business posted ($1.97) earnings per share.
Shares of SAGE traded up $0.63 during midday trading on Tuesday, reaching $126.79. 18,709 shares of the company were exchanged, compared to its average volume of 385,450. The stock has a market cap of $6.42 billion, a PE ratio of -17.70 and a beta of 2.76. SAGE Therapeutics has a 1-year low of $61.67 and a 1-year high of $195.97.
A number of research analysts recently weighed in on SAGE shares. LADENBURG THALM/SH SH set a $235.00 target price on SAGE Therapeutics and gave the company a “buy” rating in a report on Wednesday, October 31st. Oppenheimer set a $170.00 target price on SAGE Therapeutics and gave the company a “buy” rating in a report on Monday, October 29th. Canaccord Genuity set a $220.00 target price on SAGE Therapeutics and gave the company a “buy” rating in a report on Wednesday, August 8th. Stifel Nicolaus lifted their target price on SAGE Therapeutics from $198.00 to $239.00 and gave the company a “buy” rating in a report on Tuesday, August 7th. Finally, Cowen reiterated a “buy” rating and issued a $207.00 target price on shares of SAGE Therapeutics in a report on Thursday, November 1st. One analyst has rated the stock with a sell rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $203.63.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and republished in violation of international trademark and copyright laws. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/11/06/sage-therapeutics-sage-issues-earnings-results-misses-estimates-by-0-22-eps.html.
About SAGE Therapeutics
Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).
Further Reading: What is a Call Option?
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.